SM 2270
Alternative Names: SM-2270Latest Information Update: 30 Nov 2023
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Oct 2023 Preclinical trial in Solid tumours in China (Parenteral) (Beijing StarMab Biomed Technology pipeline; October 2023)